present, rather than the percentage of mutated mtDNA in leucocytes, is of major importance.
. Recently, endomysium antibodies were shown to target the enzyme tissue transglutaminase [3, 4] . In this study we investigate the value of this new marker in a large cohort of patients with Type I diabetes to identify subjects with coexisting latent or silent coeliac disease. Autoantibodies to human recombinant tissue transglutaminase were measured in 305 consecutive patients with newly diagnosed Type I diabetes (age 1 month±71 years, mean age 19.0 ± 14.5 years, 118 females, 187 males). None of them had a history of coeliac disease. Screening for tissue transglutaminase antibodies was done by combined IgG/IgA radioligand assay in a 96-well format using human recombinant [ 35 S]-methionine labelled tissue transglutaminase as described previously [5] . Receiver-operating characteristic analysis showed a diagnostic sensitivity of 95.6 % (n = 45 untreated patients with Coeliac disease and a specificity of 99.5 % (n = 574 healthy control subjects). Intra-assay and inter-assay coefficients of variation of this test were 10.4 % and 13.9 %, respectively. Where results were positive, sera were tested for IgA isotype and IgG isotype specific tissue transglutaminase antibodies [5] .
In the combined assay tissue transglutaminase antibodies were observed in 12 subjects of whom 11 (3.6 %) and 12 (3.9 %) had IgA-tissue transglutaminase antibodies and IgGtissue transglutaminase antibodies, respectively ( Table 1 ). All of the IgA-antibody positive patients were also found positive for antibodies to endomysium studied by an indirect immunofluorescence test. Patients with tissue transglutaminase antibodics were significantly younger (age 8.3 ± 4.6 years) than antibody negative diabetic subjects (18.6 ± 14.4 years) (p < 0.05). All subjects with tissue transglutaminase antibodies were clinically undetected; eight were asymptomatic and four suffered from non-specific symptoms (weight loss n = 3; recurrent abdominal pain n = 1; growth retardation n = 1; diarrhoea n = 1). The patient with positive IgG-tissue transglutaminase but negative IgA-tissue transglutaminase and endomysium antibodies suffered from IgA deficiency. Thus, in this subject only IgG-tissue transglutaminase antibodies indicate silent co- Healthy control subjects 100 0 0 TG = tissue transglutaminase a a small bowel biopsy specimen was available five TG antibody positive subjects eliac disease. Out of 12 antibody positive patient 5 gave informed consent for small-bowel biopsy. Of these subjects four had the typical histological features of coeliac disease (Type 3 lesion: flat mucosa and crypt hyperplasia) and one subject had increased intraepithelial lymphocytes (type 1 lesion) suggesting an early stage of the disease [6] . Tissue transglutaminase antibodies were detected in none of 100 healthy controls or 100 patients with newly diagnosed autoimmune thyroid disease (Hashimoto's thyroiditis n = 23; Graves' disease n = 77).
In conclusion, this study shows that the appearance of autoantibodies to tissue transglutaminase represents a specific marker to identify subjects with silent coeliac disease. These findings indicate that combined detection of IgA-tissue transglutaminase and IgG-tissue transglutaminase antibodies has the potential to overcome the limitations of the conventional endomysium antibody test including the laborious procedure of the assay, problems with assay standardisation and the restriction to the measurement of IgA isotype antibodies. The availability of this novel, non-invasive screening procedure could improve current strategies to identify undiagnosed cases of coeliac disease which is essential to prevent complications such as nutritional deficiencies, small-bowel lymphoma and other severe complications associated with this disease. Expression of kinase-inactive mutant insulin receptors does not rescue insulin receptordeficient mice from perinatal death Dear Sir, The insulin receptor mediates insulin action. Mutations of the insulin receptor give rise to insulin resistance. Lack of insulin receptors is lethal in both humans and mice [1] , although the phenotypes are different, probably as a result of developmental differences between the two species [2] . Upon insulin binding to the extracellular domain, the insulin receptor undergoes a conformational change that enables the b-subunit to bind ATP and become phosphorylated on several tyrosine residues. This event activates the receptor's kinase toward additional protein substrates and provides the underpinning for the multi-faceted actions of insulin. The pivotal role of the receptor kinase is supported by a host of studies, including naturally occurring mutations of the tyrosine kinase domain in patients with insulin resistance, site-directed mutagenesis of the cloned receptor cDNA, and the determination of the x-ray structure of the receptor's kinase domain. Nevertheless, there exist some lingering reservations as to whether the tyrosine kinase activity is a prerequisite for all insulin actions. These reservations stem from a host of studies, mostly using anti-receptor antibodies that mimic insulin action by binding to the receptor's extracellular domain, but do not activate the receptor tyrosine kinase [3±7].
To address this issue, we developed transgenic knockout mice that lack endogenous insulin receptors by virtue of being homozygous for a null allele of the receptor gene, but do express a human transgene encoding an ATP binding site mutant insulin receptor (K1030M) [8] . The mutant receptor cannot undergo autophosphorylation. We thought that, if the receptor's kinase activity is not an absolute requirement for insulin action, expression of this transgene should rescue, at least in part, the lethal phenotype due to homozygosity for the insulin receptor mutation.
Mice bearing a null IR allele (IR +/± ) were crossed with IR K1030M transgenic mice to obtain transgenic mice doubly homozygous at the targeted insulin receptor locus and at the transgenic locus (IR
). Expression of the human transgene was confirmed by immunoprecipitation of organ extracts and immunoblotting with antibodies against the insulin receptor (Fig. 1) . Transgenic knockout mice were born with the expected Mendelian distribution. Their general appearance and body weight were not different from IR ±/± mice. Within 48 h of birth, IR ±/±, K1030M and IR ±/± mice developed severe diabetic ketoacidosis, Death ensued within 3±5 days of birth. The slightly longer survival observed in this cross, compared with our previous observations, is probably due to the effect of strain±specific modifier genes and not to the transgene, since it was also observed in non±transgenic knockout mice.
In summary, expression of kinase-defective insulin receptors in mice lacking endogenous receptors does not affect the phenotype we previously reported, with lethal diabetic ketoacidosis. Thus, it is unlikely that insulin action is affected by kinase-defective receptors. There are two potential caveats in the interpretation of these results: firstly, the mutant receptor is expressed at relatively low levels in liver. Since the liver plays a crucial part in energy balance in the perinatal period,
